Takayuki Kinoshita

Takayuki Kinoshita

Auto-generated profile, based on publicly available information

Takayuki Kinoshita

Division of Breast Surgery, National Hospital Organization Tokyo Medical Center, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2010 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
TKTakayuki Kinoshita
Takayuki Kinoshita
EIEriko Iwamoto
Eriko Iwamoto
HTHitoshi Tsuda
Hitoshi Tsuda
KSKunihiko Seki
Kunihiko Seki

1 August 2016 in Clinical Breast Cancer
Verified
Journal Article
Closed access
SSSho Shiino
Sho Shiino
TKTakayuki Kinoshita
Takayuki Kinoshita
MYMasayuki Yoshida
Masayuki Yoshida
KJKenjiro Jimbo
Kenjiro Jimbo
SASota Asaga
Sota Asaga
HTHitoshi Tsuda
Hitoshi Tsuda

29 February 2016 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
MKMasaaki Kawai
Masaaki Kawai
ATAi Tomotaki
Ai Tomotaki
HMHiroaki Miyata
Hiroaki Miyata
TITakayuki Iwamoto
Takayuki Iwamoto
NNNaoki Niikura
Naoki Niikura
YTYutaka Tokuda
Yutaka Tokuda
Few studies have reported the association between body mass index (BMI) and outcome among Asian breast cancer patients. We analyzed data for 20,090 female invasive breast cancer patients who had been followed‐up for a median period of 6.7 years entered in the National Clinical Database–Breast Cancer Registry between 2004 and 2006. We used mainly theWHOcriteria forBMI (kg/m2) categories; <18.5 (underweight), ≥18.5–<21.8 (reference), ≥21.8–<25, ≥25–<30 (overweight), and ≥30 (obese). We divided normal weight patients into two subgroups because this category includes many patients compared to others. The timing ofBMImeasurement was not specified. The Cox proportional hazards model and cubic spline regression were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Smoking, alcohol, and physical activity were not controlled. A total of 1418 all‐cause, 937 breast cancer–specific deaths, and 2433 recurrences were observed. Obesity was associated with an increased risk of all‐cause (HR: 1.46; 95%CI: 1.16–1.83) and breast cancer–specific death (HR: 1.47; 95%CI: 1.11–1.93) for all patients, and with all‐cause (HR: 1.47; 95%CI: 1.13–1.92) and breast cancer–specific death (HR: 1.58; 95%CI: 1.13–2.20) for postmenopausal patients. Being underweight was associated with an increased risk of all‐cause death for all (HR: 1.41; 95%CI: 1.16–1.71) and for postmenopausal patients (HR: 1.45; 95%CI: 1.15–1.84). With regard to subtype and menopausal status, obesity was associated with an increased risk of breast cancer–specific death for all cases of luminal B tumor (HR: 2.59; 95%CI: 1.51–4.43; Pheterogeneityof Luminal B vs. Triple negative = 0.016) and for postmenopausal patients with luminal B tumor (HR: 3.24; 95%CI: 1.71–6.17). Being obese or underweight is associated with a higher risk of death among female breast cancer patients in Japan.

6 August 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
TKTakayuki Kinoshita
Takayuki Kinoshita
TNTakahiro Nakayama
Takahiro Nakayama
EFEisuke Fukuma
Eisuke Fukuma
MIMasafumi Inokuchi
Masafumi Inokuchi
HIHiroshi Ishiguro
Hiroshi Ishiguro
MTMasakazu Toi
Masakazu Toi
Purpose: This study aimed to assess the efficacy of scalp-cooling devices in preventing chemotherapy-induced alopecia in Japanese breast cancer patients and investigate whether a scalp-cooling device improves hair volume recovery over a 12 weeks period after completing chemotherapy. Methods: This multicenter controlled trial included women with breast cancer undergoing chemotherapy in Japan between February 2016 and March 2018. The primary endpoint was the proportion of patients with no alopecia at the end of chemotherapy. The secondary endpoint included hair volume at 12 weeks after completing chemotherapy. Results: A total of 48 patients were enrolled; of them, 34 and 14 were sequentially allocated to the scalp-cooling group using the Paxman Hair Loss Prevention System and the control group, respectively. There was no significant difference in average age between the scalp-cooling and the control groups (50.0 ± 9.6 vs. 49.0 ± 9.0 years). More than 50% of patients in each group had stage II breast cancer (scalp-cooling group: 53.1%; control group: 64.3%), more than 90% received adjuvant chemotherapy (scalp-cooling group: 96.9%; control group: 92.9%), and more than 60% were treated with a docetaxel/cyclophosphamide regimen (scalp-cooling group: 75.0%; control group: 64.3%). There were more patients judged to have no alopecia at the end of chemotherapy in the scalp-cooling group than in the control group (26.7% [8/30] vs. 0% [0/13]; P = 0.011). The proportion of patients with alopecia who experienced an increase in hair volume of ≥50% within 12 weeks duration after chemotherapy was 85.7% (24/28) in the scalp-cooling group and 50.0% (6/12) in the control group. No patient developed serious adverse events related to the scalp-cooling device. Conclusions: The use of a scalp-cooling device prevented alopecia with acceptable safety for Japanese patients. In addition, scalp cooling resulted in faster recovery of hair volume after chemotherapy, even in patients for whom scalp cooling failed to prevent chemotherapy-induced alopecia.

1 January 2007 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
TKTakayuki Kinoshita
Takayuki Kinoshita
Background Despite the increasing use of both sentinel lymph node (SLN) biopsy and neoadjuvant chemotherapy (NAC) in patients with operable breast cancer, information on the feasibility and accuracy...